Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial.

Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J

The Journal of clinical endocrinology and metabolism20 May 2008Cited by 132 (Europe PMC)

PMID18492760DOI10.1210/jc.2008-0315PepBankPUB-18492760

Source link PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acromegaly, postoperative cure occurred in 14/31 (45%) with octreotide pretreatment versus 7/30 (23%) with direct surgery (P=0.11).
In plain wordsIn acromegaly, cure was numerically more frequent after octreotide pretreatment than direct surgery, without statistical significance.
Peptide
Octreotide
Outcome
IncreasePostoperative cure by IGF-I
Study
n = 61
Comparator
Direct surgery
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg every 28th day · intramuscular · 6 monthsAs given in this study (human).
Measurements
Cure rate by IGF-I criteria
45%
octreotide pretreatment, 14 of 31
Cure rate by IGF-I criteria
23%
direct surgery, 7 of 30
Between-group p-value
0.11 p
pretreatment versus direct surgery
Source sentences
Summary
According to the IGF-I criteria, 14 of 31 (45%) pretreated patients vs. seven of 30 (23%) patients with direct surgery were cured by surgery (P = 0.11).
2 context sentences(design, population, supporting numbers)
Summary · context
After a baseline evaluation, patients were randomized directly to transsphenoidal surgery (n = 30) or pretreatment with octreotide (n = 32) 20 mg im every 28th day for 6 months before transsphenoidal surgery.
Summary · context
Cure was evaluated 3 months postoperatively primarily by IGF-I levels.
Report a problemFND-1849276001
02HumanRandomized controlled trialEfficacy outcome
In acromegalic macroadenomas, cure occurred in 13/26 (50%) with octreotide pretreatment versus 4/25 (16%) with direct surgery (P=0.017).
In plain wordsIn acromegalic macroadenomas, cure was more frequent after octreotide pretreatment than direct surgery.
Peptide
Octreotide
Outcome
IncreasePostoperative cure in macroadenomas
Study
n = 51
Comparator
Direct surgery
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg every 28th day · intramuscular · 6 monthsAs given in this study (human).
Measurements
Cure rate by IGF-I criteria
50%
macroadenomas, octreotide pretreatment, 13 of 26
Cure rate by IGF-I criteria
16%
macroadenomas, direct surgery, 4 of 25
Between-group p-value
0.017 p
macroadenomas, pretreatment versus direct surgery
Source sentences
Summary
In patients with macroadenomas, 13 of 26 (50%) pretreated vs. four of 25 (16%) with direct surgery were cured (P = 0.017).
2 context sentences(design, population, supporting numbers)
Summary · context
After a baseline evaluation, patients were randomized directly to transsphenoidal surgery (n = 30) or pretreatment with octreotide (n = 32) 20 mg im every 28th day for 6 months before transsphenoidal surgery.
Summary · context
Cure was evaluated 3 months postoperatively primarily by IGF-I levels.
Report a problemFND-1849276003
03HumanRandomized controlled trialEfficacy outcome
In acromegalic microadenomas, cure occurred in 1/5 (20%) with octreotide pretreatment versus 3/5 (60%) with direct surgery (P=0.52).
In plain wordsIn acromegalic microadenomas, cure was numerically less frequent after octreotide pretreatment than direct surgery, without statistical significance.
Peptide
Octreotide
Outcome
DecreasePostoperative cure in microadenomas
Study
n = 10
Comparator
Direct surgery
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg every 28th day · intramuscular · 6 monthsAs given in this study (human).
Measurements
Cure rate by IGF-I criteria
20%
microadenomas, octreotide pretreatment, 1 of 5
Cure rate by IGF-I criteria
60%
microadenomas, direct surgery, 3 of 5
Between-group p-value
0.52 p
microadenomas, pretreatment versus direct surgery
Source sentences
Summary
In patients with microadenomas (< or = 10 mm), one of five (20%) pretreated vs. three of five (60%) with direct surgery were cured (P = 0.52).
2 context sentences(design, population, supporting numbers)
Summary · context
After a baseline evaluation, patients were randomized directly to transsphenoidal surgery (n = 30) or pretreatment with octreotide (n = 32) 20 mg im every 28th day for 6 months before transsphenoidal surgery.
Summary · context
Cure was evaluated 3 months postoperatively primarily by IGF-I levels.
Report a problemFND-1849276002

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00521300

Preoperative Octreotide Treatment of Acromegaly

St. Olavs Hospitaln = 62Sept 1999 to May 2010

Acromegaly

Trial page ClinicalTrials.govUpdated 2 Jun 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.